269 related articles for article (PubMed ID: 19889883)
1. Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids.
Mohamed MF; Frye RF
Drug Metab Dispos; 2010 Feb; 38(2):270-5. PubMed ID: 19889883
[TBL] [Abstract][Full Text] [Related]
2. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.
Picard N; Ratanasavanh D; Prémaud A; Le Meur Y; Marquet P
Drug Metab Dispos; 2005 Jan; 33(1):139-46. PubMed ID: 15470161
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
Lau AJ; Chang TK
Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
[TBL] [Abstract][Full Text] [Related]
4. Effect of Ginkgo biloba extract on rat hepatic microsomal CYP1A activity: role of ginkgolides, bilobalide, and flavonols.
Kuo If; Chen J; Chang TK
Can J Physiol Pharmacol; 2004 Jan; 82(1):57-64. PubMed ID: 15052306
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mycophenolic acid glucuronidation by niflumic acid in human liver microsomes.
Vietri M; Pietrabissa A; Mosca F; Pacifici GM
Eur J Clin Pharmacol; 2002 May; 58(2):93-7. PubMed ID: 12012139
[TBL] [Abstract][Full Text] [Related]
6. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1.
Chang TK; Chen J; Yeung EY
Toxicol Appl Pharmacol; 2006 May; 213(1):18-26. PubMed ID: 16226778
[TBL] [Abstract][Full Text] [Related]
7. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes.
Shipkova M; Strassburg CP; Braun F; Streit F; Gröne HJ; Armstrong VW; Tukey RH; Oellerich M; Wieland E
Br J Pharmacol; 2001 Mar; 132(5):1027-34. PubMed ID: 11226133
[TBL] [Abstract][Full Text] [Related]
8. Interactions of pharmacokinetic profile of different parts from Ginkgo biloba extract in rats.
Guan H; Qian D; Ren H; Zhang W; Nie H; Shang E; Duan J
J Ethnopharmacol; 2014 Aug; 155(1):758-68. PubMed ID: 24953034
[TBL] [Abstract][Full Text] [Related]
9. Identification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leaves.
Sloley BD; Urichuk LJ; Morley P; Durkin J; Shan JJ; Pang PK; Coutts RT
J Pharm Pharmacol; 2000 Apr; 52(4):451-9. PubMed ID: 10813558
[TBL] [Abstract][Full Text] [Related]
10. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats.
Deng Y; Bi HC; Zhao LZ; He F; Liu YQ; Yu JJ; Ou ZM; Ding L; Chen X; Huang ZY; Huang M; Zhou SF
Xenobiotica; 2008 May; 38(5):465-81. PubMed ID: 18421621
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of human UDP-glucuronosyltransferases responsible for the in-vitro glucuronidation of arctigenin.
Xin H; Xia YL; Hou J; Wang P; He W; Yang L; Ge GB; Xu W
J Pharm Pharmacol; 2015 Dec; 67(12):1673-81. PubMed ID: 26407805
[TBL] [Abstract][Full Text] [Related]
12. Distinct role of bilobalide and ginkgolide A in the modulation of rat CYP2B1 and CYP3A23 gene expression by Ginkgo biloba extract in cultured hepatocytes.
Chang TK; Chen J; Teng XW
Drug Metab Dispos; 2006 Feb; 34(2):234-42. PubMed ID: 16258077
[TBL] [Abstract][Full Text] [Related]
13. Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices?
Balogh A; Merkel U; Müller D
Exp Toxicol Pathol; 2003 Jun; 54(5-6):375-9. PubMed ID: 12877348
[TBL] [Abstract][Full Text] [Related]
14. Modulation of CYP1A1 activity by a Ginkgo biloba extract in the human intestinal Caco-2 cells.
Ribonnet L; Callebaut A; Nobels I; Scippo ML; Schneider YJ; De Saeger S; Pussemier L; Larondelle Y
Toxicol Lett; 2011 May; 202(3):193-202. PubMed ID: 21329749
[TBL] [Abstract][Full Text] [Related]
15. Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid.
Miles KK; Kessler FK; Smith PC; Ritter JK
Drug Metab Dispos; 2006 Sep; 34(9):1632-9. PubMed ID: 16790558
[TBL] [Abstract][Full Text] [Related]
16. Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse.
Al Saabi A; Allorge D; Sauvage FL; Tournel G; Gaulier JM; Marquet P; Picard N
Drug Metab Dispos; 2013 Mar; 41(3):568-74. PubMed ID: 23230132
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms.
Uchihashi S; Fukumoto H; Onoda M; Hayakawa H; Ikushiro S; Sakaki T
Drug Metab Dispos; 2011 May; 39(5):803-13. PubMed ID: 21346002
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway.
Kerdpin O; Knights KM; Elliot DJ; Miners JO
Biochem Pharmacol; 2008 Jul; 76(2):249-57. PubMed ID: 18541222
[TBL] [Abstract][Full Text] [Related]
19. In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes.
Oliveira EJ; Watson DG
FEBS Lett; 2000 Apr; 471(1):1-6. PubMed ID: 10760502
[TBL] [Abstract][Full Text] [Related]
20. An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity.
Miles KK; Stern ST; Smith PC; Kessler FK; Ali S; Ritter JK
Drug Metab Dispos; 2005 Oct; 33(10):1513-20. PubMed ID: 16033946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
